(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 16.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 97.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.83%.
Karyopharm Therapeutics's revenue in 2025 is $142,530,000.On average, 8 Wall Street analysts forecast KPTI's revenue for 2025 to be $2,571,101,592, with the lowest KPTI revenue forecast at $2,428,556,269, and the highest KPTI revenue forecast at $2,709,554,705. On average, 8 Wall Street analysts forecast KPTI's revenue for 2026 to be $2,535,294,752, with the lowest KPTI revenue forecast at $2,195,641,303, and the highest KPTI revenue forecast at $2,904,446,218.
In 2027, KPTI is forecast to generate $4,250,101,352 in revenue, with the lowest revenue forecast at $3,119,116,747 and the highest revenue forecast at $6,209,588,022.